Breast Cancer

Macrophage sensitivity to bexmarilimab-induced reprogramming is shaped by the tumor microenvironment
Jenna H Rannikko, Rita Turpin, Pia Boström, Reetta Virtakoivu, Chantal Harth, Akira Takeda, Anselm Tamminen, Ilkka Koskivuo, Maija Hollmén

Journal for ImmunoTherapy of Cancer May 2025, 13 (5) e011292; DOI: 10.1136/jitc-2024-011292
Tumor-infiltrating mast cells as potential chemoimmunotherapy enhancer in triple-negative breast cancer
Pinchao Fan, Chengjun Zhu, Xiaoxiang Guan

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e011899; DOI: 10.1136/jitc-2025-011899
Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer
Bi-Cheng Wang

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e012312; DOI: 10.1136/jitc-2025-012312
Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study
Kamran A Ahmed, Younchul Kim, Sungjune Kim, Min Hsuan Wang, Michelle DeJesus, John A Arrington, Aixa E Soyano, Avan J Armaghani, Ricardo L B Costa, Loretta S Loftus, Marilin Rosa, Jimmy J Caudell, Roberto Diaz, Arnold B Etame, Nam D Tran, Hatem Soliman, Brian J Czerniecki, Peter A Forsyth, Hsiang-Hsuan Michael Yu, Hyo S Han

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e011432; DOI: 10.1136/jitc-2024-011432
Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer
Yilin Chen, Lu Yang, Yuhong Huang, Teng Zhu, Liulu Zhang, Minyi Cheng, Cangui Wu, Peiyong Li, Minting Liang, Xiaoqi Zhang, Hao Peng, Kun Wang

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e010365; DOI: 10.1136/jitc-2024-010365
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapy
Nicole J Toney, Megan T Lynch, Filipa Lynce, Candace Mainor, Claudine Isaacs, Jeffrey Schlom, Renee N Donahue

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e011379; DOI: 10.1136/jitc-2024-011379
Memory-promoting function of miR-379-5p attenuates CD8⁺ T cell exhaustion by targeting immune checkpoints
You-Zhe Lin, Chia-Hsin Liu, Wan-Rong Wu, Ting-Yi Liao, Chuan-Chun Lee, Hong-Wei Li, Feng-Chi Chung, Yi-Chun Shen, Guan-Yu Zhuo, Liang-Chih Liu, Wei-Chung Cheng, Shao-Chun Wang

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e010363; DOI: 10.1136/jitc-2024-010363
Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer
Ying Jiang, Zhiwen Qian, Cenzhu Wang, Danping Wu, Lu Liu, Xin Ning, Yilan You, Jie Mei, Xiaoqian Zhao, Yan Zhang

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e010924; DOI: 10.1136/jitc-2024-010924
Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial
Meiting Chen, Riqing Huang, Qixiang Rong, Wei Yang, Xiujiao Shen, Qi Sun, Ditian Shu, Kuikui Jiang, Cong Xue, Jing Peng, Xin An, Haifeng Li, Fei Xu, Yanxia Shi

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e011314; DOI: 10.1136/jitc-2024-011314
β-blocker suppresses both tumoral sympathetic neurons and perivascular macrophages during oncolytic herpes virotherapy
Konstantina Kyritsi, Rafal Pacholczyk, Eugene Douglass, Miao Yu, Hui Fang, Gang Zhou, Balveen Kaur, Qin Wang, David H Munn, Bangxing Hong

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e011322; DOI: 10.1136/jitc-2024-011322

Main menu

Breast Cancer

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Breast Cancer

Pages